Alaunos Therapeutics, Inc. (TCRT) stock
TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.72+0.06 (+3.61%)
Close on Nov 18, 2026Market cap $4.37MP/E –Yield –
Alaunos Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Alaunos Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$4.06M. For fiscal 2025 it was -$4.23M. The highest annual figure on record is -$4.23M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.23M | – |
| FY2024 | Dec 31, 2024 | -$4.81M | – |
| FY2023 | Dec 31, 2023 | -$34.27M | – |
| FY2022 | Dec 31, 2022 | -$35.11M | – |
| FY2021 | Dec 31, 2021 | -$77.55M | – |
| FY2020 | Dec 31, 2020 | -$80.36M | – |
| FY2019 | Dec 31, 2019 | -$57.86M | – |
| FY2018 | Dec 31, 2018 | -$53.91M | – |
| FY2017 | Dec 31, 2017 | -$53.49M | – |
| FY2016 | Dec 31, 2016 | -$165.31M | – |
| FY2015 | Dec 31, 2015 | -$120.10M | – |
| FY2014 | Dec 31, 2014 | -$43.50M | – |
| FY2013 | Dec 31, 2013 | -$57.71M | – |
| FY2012 | Dec 31, 2012 | -$102.17M | – |
| FY2011 | Dec 31, 2011 | -$71.40M | – |
| FY2010 | Dec 31, 2010 | -$24.55M | – |
| FY2009 | Dec 31, 2009 | -$12.12M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$952.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.01M | – |
| Q4 FY2025 | Dec 31, 2025 | -$907.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.19M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.04M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$755.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.15M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.17M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.74M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.95M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.66M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.98M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.67M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.52M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.23M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.09M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.05M | – |
| Q1 FY2021 | Jun 30, 2021 | -$44.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$22.77M | – |
| Q3 FY2020 | Sep 30, 2020 | -$20.32M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.61M | – |
| Q1 FY2020 | Mar 31, 2020 | -$18.66M | – |
| Q4 FY2019 | Dec 31, 2019 | -$16.04M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.45M | – |
| Q2 FY2019 | Jun 30, 2019 | -$14.75M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.62M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.76M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.57M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.38M | – |
| Q1 FY2018 | Mar 31, 2018 | -$16.20M | – |
| Q4 FY2017 | Dec 31, 2017 | -$13.44M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.08M | – |
| Q2 FY2017 | Jun 30, 2017 | -$13.01M | – |
| Q1 FY2017 | Mar 31, 2017 | -$13.97M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.11M | – |
| Q3 FY2016 | Sep 30, 2016 | -$10.91M | – |
| Q2 FY2016 | Jun 30, 2016 | -$131.24M | – |
See a number that looks wrong?